Navigation Links
Virginia Woolf and Neuropsychiatry

Virginia Woolf and Neuropsychiatry, written by Maxwell Bennett, one of the leaders in the field of neurosciences, provides an explanation of the symptoms and untimely suicide of one of literature's greatest authors, Virginia Woolf. The sources used are letters and statements from Woolf herself, the literature she wrote and comments, letters and other documentation that refers to her mental state and her medical status. The author uses current insights into depression, the mental consequences of child abuse and drug interactions/effects to examine her life.

The second part of the book provides a neuropsychiatric analysis of the state of present knowledge concerning what goes awry in the functioning of the brain in depression, particularly leading to suicide. Five essays, aimed at specialists in neuropsychiatry, show how far we have probed brain functions related to major psychiatric problems.

Maxwell Bennett said: "Because of her literary genius, we find in her novels, plays, critical reviews, autobiographical sketches and diaries an unparalleled insight into the mind of someone destined to end their life. These offer those concerned with mitigating the incidence of suicide a unique opportunity to consider the circumstances and familial burdens that promote severe depression and so design programs that will ameliorate them."

M. R. Bennett AO is Professor of Neuroscience and University Chair at the University of Sydney, Founding Director of the Brain and Mind Research Institute and Adjunct Professor of Neuropsychiatry. He is the author of many papers and books in neuroscience and neuropsychiatry, including The Idea of Consciousness (1997) and a History of the Synapse (2001) as well as more recently Philosophical Foundations of Neuroscience (2003) and History of Cognitive Neuroscience (2008) with his colleague Peter Hacker. Maxwell Bennett is the recipient of numerous awards for his research in neuroscience.


Contact: Joan Robinson

Page: 1

Related biology news :

1. Virginia Tech computer scientists develop new way to study molecular networks
2. TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
3. Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia
4. Scientific meeting at Virginia Tech will make more than $2 million economic impact
5. Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium
6. Biology professor secures grant to save West Virginias primary natural history collection
7. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
Post Your Comments:
Related Image:
Virginia Woolf and Neuropsychiatry
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: